Gland Pharma Q1FY27 Results Update | Insight

Skip to main content

Loading...

Insights|Newsletter|

Gland Pharma Q1FY27 Results Update

Midas Equities and Research

11 August 2026

10 min read

Gland Pharma Q1FY27 Results Update

Let’s Spark a
conversation

Whether you're an investor seeking disciplined strategies or a business exploring growth capital, we'd welcome a conversation.

Get in Touch

All fields are required. After submit, a confirmation message appears below the button.

First name

Last name

Email address

Who We Are

About Spark Capital Group

Why Spark Capital?

Careers

Events

Regulatory Information

What We Do

Private Wealth Management

Investment Banking

Asset Management

Whom We Serve

Individual Families

Family Offices

Corporates

Get In Touch

Contact Us

Register A Complaint

Consolidated Investor Charter

Spark Capital Advisors (India) Private Limited (SCA) has gone through a process of reorganisation in 2022 and demerged its institutional equities business (stock broking license and research analyst license) to Spark Institutional Equities Private Limited (SIEPL) through a Composite Scheme of Demerger. Further the shares of SIEPL have been bought by Avendus Capital Private Limited with effect from December 20, 2022. SCA, its affiliates and its related parties, do not have any connection or relation with SIEPL

All Rights reserved. Copyright © 2026.
SPARK CAPITAL ADVISORS (INDIA) PVT LTD

Terms of Use|Privacy Policy

Spark Capital

Spark Capital
PWM

Spark Asset
Management

Spark Capital

Gland Pharma Q1FY27 Results Update | Insight